Long-term safety of Velsipity for ulcerative colitis
Part of Digestive system clinical trials.
This study watches people with ulcerative colitis who are taking Velsipity (a medicine) for the first time. It aims to learn how the drug works and what side effects might happen over the long term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe ulcerative colitis.
- You started taking Velsipity for the first time after October 2022.
- You have not been in a clinical study for Velsipity before.
- You understand the study and agree to share your health information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called LIV001 in people with mild-to-moderate ulcerative colitis. It aims to see if the medicine can help calm inflammation in the colon and improve symptoms.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
This trial tests whether two medications, vedolizumab (a biologic given by IV) and upadacitinib (a pill), work together to help people with moderate to severe ulcerative colitis. The goal is to see if this combination is safe and effective for controlling symptoms and healing the colon.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.